Currently, we observe an increase in the number of transcatheter aortic valve replacement (TAVR) procedures due to its expansion toward a younger population with lower risk. For this reason, it is crucial to maintain continuous technological innovation to minimize post-procedural complications. The FDA has approved the SavyWire, a preformed 0.035-caliber guidewire that offers three essential<a href="https://solaci.org/en/2023/12/14/safe-tavi-study-safety-and-efficacy-of-the-pressure-sensor-and-pacing-guidewire/" title="Read more" >...</a>
TAVI-in-TAVI with Balloon-Expandable Valves
TAVI (Transcatheter Aortic Valve Implantation) has proven to be beneficial and is currently performed in increasingly younger and lower-risk patients. However, as with surgical bioprostheses, structural deterioration, whether due to stenosis or regurgitation, is one of the challenges we must address. While currently uncommon, this is an issue we will probably see more and more<a href="https://solaci.org/en/2023/09/12/tavi-in-tavi-with-balloon-expandable-valves/" title="Read more" >...</a>
Post-TAVI Prosthesis-Patient Mismatch
Prosthesis-patient mismatch (PPM) occurs when the effective orifice area (EOA) after valve placement is significantly smaller compared with the patient’s body surface area (BSA), resulting in an increased transprosthetic residual gradient. The presence of PPM, especially in various surgical series, has been associated with long-term adverse clinical events. In relation to transcatheter aortic valve implantation<a href="https://solaci.org/en/2023/09/06/post-tavi-prosthesis-patient-mismatch/" title="Read more" >...</a>
SOLACI-SBHCI 2023 | TAVI – Minimizing Risks, Optimizing Outcomes & Impact of the Index Procedure on Future Options – Dr. Ole De Backer
Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Ole De Backer, entitled “TAVI – Minimizing Risks, Optimizing Outcomes & Impact of the Index Procedure on Future Options”
TAVI in Moderate Aortic Stenosis with Low Ejection Fraction
The presence of aortic stenosis, heart failure, and decreased ventricular function is associated with poor prognosis and high mortality. For this reason, both European and American guidelines classify severe stenosis as a Class I indication. There are two retrospective analyses that demonstrate the benefits of transcatheter aortic valve implantation (TAVI) via transfemoral access. The TAVR<a href="https://solaci.org/en/2023/06/16/tavi-in-moderate-aortic-stenosis-with-low-ejection-fraction/" title="Read more" >...</a>
TAVI INDICAÇÕES E RESULTADOS ATUAIS
Por Dr. Luiz Antonio Carvalho.
Software “syngo Aortic Valve Guidance”para procedimentos de TAVI
By Dr. Ari Mandil.
Complex Cases in TAVI Our Experience With the Last Generation Valves
By Dr. Vinícius Esteves.
SURTAVI at 5 Years
Transcatheter aortic valve replacement (TAVR) by transfemoral access has shown great benefit for different risk groups, but its long-term durability is still uncertain. Available evidence comes from small analysis and a single randomized trial with 280 patients and an 8 year follow-up: the NOTION Trial, where TAVR showed less valvular degeneration than aortic valve replacement (AVR) surgery.<a href="https://solaci.org/en/2022/10/17/surtavi-at-5-years/" title="Read more" >...</a>
TCT 2022 | FRANCE-TAVI Registry: Small Annuli
The presence of small annuli, defined in this registry as < 23 mm diameter or indexed diameter <12 mm/m2 by CT, continues to be one of the greatest challenges of both surgical and endovascular aortic valve treatments. The FRANCE-TAVI Registry looked at 1,195 patients presenting small annuli. 895 (74.9%) received balloon expandable valves (BEV) and<a href="https://solaci.org/en/2022/09/21/tct-2022-france-tavi-registry-small-annuli/" title="Read more" >...</a>